Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Finished Goods (2025)

Crinetics Pharmaceuticals has reported Finished Goods over the past 1 years, most recently at $18000.0 for Q4 2025.

  • For Q4 2025, Finished Goods changed N/A year-over-year to $18000.0; the TTM value through Dec 2025 reached $18000.0, changed N/A, while the annual FY2025 figure was $18000.0, N/A changed from the prior year.
  • Finished Goods for Q4 2025 was $18000.0 at Crinetics Pharmaceuticals.
  • Over five years, Finished Goods peaked at $18000.0 in Q4 2025 and troughed at $18000.0 in Q4 2025.